SGLT2 Inhibition in T2DM Management: Current Position and Future Promise
|
|
- Derek Stewart
- 5 years ago
- Views:
Transcription
1 SGLT2 Inhibition, Diabetes and CVD: Where Does This Fit in CV Risk Management? ESC Congress, Rome, Italy 28 August, 2016 SGLT2 Inhibition in T2DM Management: Current Position and Future Promise Silvio E. Inzucchi MD Yale School of Medicine Yale-New Haven Hospital New Haven, Connecticut, USA
2 Silvio E. Inzucchi MD Profess of Medicine (Endocrinology) Disclosure of potential conflicts of interest Research contracts: Boehringer Ingelheim Stra Zeneca Janssen (TIMI Group) Daiichi Sankyo Takeda (study supplies) Eisai (TIMI Group) Consulting: Merck Sanofi/Lexicon Poxel VTV Therapeutics Employment in industry: None Stockholder of healthcare company: Owner of healthcare company: None None Other: Novo Ndisk (Trial DMC member) Intarcia (Trial DMC member)
3 One Half- Century of Marketed Drugs f Hypertension and Type 2 Diabetes in the United States Adapted from: Inzucchi SE. Comparing and Choosing Oral Agents, in Clinical Diabetes, Fonseca VA, WB Saunders, 2006.
4 Multiple Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption - HYPERGLYCEMIA pancreatic insulin secretion pancreatic glucagon secretion? hepatic glucose production Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine 2011 renal glucose excretion - peripheral glucose uptake
5 Multiple Pathophysiologically-Based Therapies f T2DM GLP-1R Insulin agonists incretin Glinides S U s effect DPP-4 Amylin inhibits mimetics guta G I s carbohydrate delivery & absption Bile acid sequestrants hepatic glucose production Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA SGLT-2 inhibits - DA agonists T Z D s? peripheral glucose uptake
6 The 7 Maj Glucose-Lowering Drug Classes in Use in Patients with T2DM in US & Europe GLP-1R agonists incretin effect DPP-4 inhibits gut carbohydrate delivery & absption - Insulin pancreatic S U s insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA - T Z D s? hepatic glucose production Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine 2011 SGLT-2 inhibits peripheral glucose uptake
7 = 7 GLP-1R agonists DPP-4 inhibits incretin enhancers Insulin S U s insulin providers insulin sensitizers T Z D s SGLT-2 inhibits glucose excreter
8 Renal Glucose Handling* Rate of Glucose Filtration/ Reabsption/Excretion (mg/min) Tmax Threshold Filtered Excreted Reabsbed T m Threshold (Tm Glu ) = maximal resptive capacity of the proximal tubule Plasma Glucose (mg/dl) Schematic representation of the typical titration curve f renal glucose reabsption in man. Adapted from Silverman M, Turner RJ. Handbook of Physiology, Oxfd University Press; 1992: *Filters & reabsbs g glucose/day
9 Active (SGLT2) & Passive (GLUT2) Glucose Transpt in Renal Proximal Tubular Cell Nair S, et al. J Clin Endocrinol Metab. 2010;95: Tubular lumen Interstitium Na Glucose SGLT2 K Na ATPase Glucose Na -K Pump Na GLUT2 Glucose
10 Glucose filtration Nmal Physiology of Renal Glucose Homeostasis Glomerulus Proximal tubule S1 SGLT2 SGLT1 S3 Distal tubule Collecting duct Glucose reabsption 90% 10% Loop of Henle Minimal glucose excretion Wright EM. Am J Physiol Renal Physiol. 2001;280:F10-F18; Lee YJ et al. Kidney Int Suppl. 2007;106:S27-S35; Han S. Diabetes. 2008;57:
11 Glucose filtration SGLT2 Inhibition Reduces Renal Glucose Reabsption Glomerulus Proximal tubule S1 SGLT2 SGLT1 S3 Distal tubule Collecting duct Glucose reabsption 90% SGLT2 inhibit 10% Loop of Henle Increased glucose excretion g/day ( Kcal/day) Wright EM. Am J Physiol Renal Physiol. 2001;280:F10-F18; Lee YJ et al. Kidney Int Suppl. 2007;106:S27-S35; Han S. Diabetes. 2008;57:
12 SGLT2 Inhibits Currently Available Canagliflozin (100, 300 mg) Dapagliflozin (5, 10 mg) Empagliflozin (10, 20 mg) Ipragliflozin, Luseogliflozin, Tofogliflozin (Japan) Ertugliflozin (investigational)
13 Adjusted mean (95% CI) difference versus placebo in change from baseline in HbA 1c (%) Placebo-crected change from baseline in HbA1c 0,00-0,25-0,50-0,75-1,00-1,25 Dapagliflozin Canagliflozin Empagliflozin Ipragliflozin Luseogliflozin Dapagliflozin (~ 6000 patients) 0.56 ( 0.64 to 0.48) Canagliflozin (~ 3500 patients) 0.81 ( 0.93 to 0.69) Empagliflozin (~ 4000 patients) 0.65 ( 0.74 to 0.56) Ipragliflozin (~ 1000 patients) 0.97 ( 1.23 to 0.70) Luseogliflozin (~ 500 patients) 0.70 ( 0.85 to 0.55) Pooled results f 22 dapagliflozin, 11 empagliflozin, 9 canagliflozin, 7 ipragliflozin and 3 luseogliflozin studies with 12 weeks duration from published and gray literature sources through June 30, 2014 [search strategy adapted from Vasilakou et al. Ann Intern Med. 2013;159(4): ]. Results are presented f the group allocated to the highest, most common dose across studies. SGLT2: sodium glucose cotranspter 2, CI: confidence interval, HbA 1c : haemoglobin A 1c. Courtesy, A. Tsapas MD, Aristotle Univ, Thessaloniki, Greece Vasilakou D, et al. Ann Intern Med. 2013;159: Inverse-variance weighted random effects meta-analysis
14 Adjusted mean (95% CI) difference versus placebo in change from baseline in body weight (kg) Placebo-crected change from baseline in body weight 0,00-0,50-1,00-1,50-2,00-2,50 Overall Monotherapy Add-on treatment Overall Monotherapy Add-on treatment 1.87 ( 2.05 to 1.70) 1.72 ( 1.92 to 1.52) 2.02 ( 2.28 to 1.75) Pooled results f 18 studies of SGLT2 inhibits as monotherapy and 28 studies as add-on treatment with 12 weeks duration from published and gray literature sources through June 30, 2014 [search strategy adapted from Vasilakou et al. Ann Intern Med. 2013;159(4): ]. Results are presented f the group allocated to the highest, most common dose across studies. SGLT2: sodium glucose cotranspter 2, CI: confidence interval. Courtesy, A. Tsapas MD, Aristotle Univ, Thessaloniki, Greece Vasilakou D, et al. Ann Intern Med. 2013;159: Inverse-variance weighted random effects meta-analysis
15 Adjusted mean (95% CI) difference versus placebo in change from baseline in SBP (mm Hg) Placebo-crected change from baseline in systolic blood pressure (SBP) 0,00-1,00-2,00-3,00-4,00-5,00-6,00 Overall Monotherapy Add-on treatment Overall Monotherapy Add-on treatment 4.19 ( 4.77 to 3.61) 4.74 ( 5.52 to 3.95) 3.91 ( 4.68 to 3.14) Pooled results f 16 studies of SGLT2 inhibits as monotherapy and 29 studies as add-on treatment with 12 weeks duration from published and gray literature sources through June 30, 2014 [search strategy adapted from Vasilakou et al. Ann Intern Med. 2013;159(4): ]. Results are presented f the group allocated to the highest, most common dose across studies. SGLT2: sodium glucose cotranspter 2, CI: confidence interval. Courtesy, A. Tsapas MD, Aristotle Univ, Thessaloniki, Greece Vasilakou D, et al. Ann Intern Med. 2013;159: Inverse-variance weighted random effects meta-analysis
16 Adjusted mean (95% CI) difference versus placebo in change from baseline in DBP (mm Hg) Placebo-crected change from baseline in diastolic blood pressure (DBP) 0,00-0,50-1,00-1,50-2,00-2,50-3,00 Overall Monotherapy Add-on treatment Overall Monotherapy Add-on treatment 2.02 ( 2.30 to 1.74) 2.03 ( 2.56 to 1.50) 2.03 ( 2.38 to 1.68) Pooled results f 14 studies of SGLT2 inhibits as monotherapy and 27 studies as add-on treatment with 12 weeks duration from published and gray literature sources through June 30, 2014 [search strategy adapted from Vasilakou et al. Ann Intern Med. 2013;159(4): ]. Results are presented f the group allocated to the highest, most common dose across studies. SGLT2: sodium glucose cotranspter 2, CI: confidence interval. Courtesy, A. Tsapas MD, Aristotle Univ, Thessaloniki, Greece Vasilakou D, et al. Ann Intern Med. 2013;159: Inverse-variance weighted random effects meta-analysis
17 Empagliflozin vs. glimepiride as add-on to metfmin After 2 years (n = 1,549): Me durable reduction in HbA 1c ( 0.11 %; 95% CI 0.19, 0.02). Significant body weight reduction of 4.5 kg (95% CI 4.8, 4.1). Lowering effect on SBP was 5.6 mm Hg (95% CI 6.8, 4.4). 6-fold fewer hypoglycemic events with empagliflozin (4%) than with glimepiride (25%). Similar rates of urinary tract infections but increased incidence of genital mycotic infections f empagliflozin (12%) compared with glimepiride (2%). Ridderstra le M et al. Lancet Diabetes Endocrinol. 2014;2(9):
18 SGLT2 Inhibits: Risks vs. Benefit Assessment Befe Results of CVOTs BENEFITS Insulin-independent BGlowering effect (irrespective of disease duration) Low hypoglycemia rates Modest weight, BMI, WC Modest BP Albumin:Cr Ratio Modest TGs Small HDL-C RISKS Genital mycotic infections? UTIs DKA Polyuria/ dehydration Reversible GFR Small LDL-C Fracture risk (?) Kim Y et al. Diabetes Metab Syndr Obes. 2012;5: ; Inzucchi SE et al. Diabetes Care 2015;38:
19 Potential pathways to CV benefits of SGLT2-inhibits based on clinical and mechanistic studies BP Arterial stiffness Novel Pathways (?) Albuminuria SNS activity(?) Weight Visceral adiposity Glucose Insulin Oxidative stress Uric Acid LDL-C HDL-C TGs Inzucchi SE et al. Diab Vasc Dis Res 2015;12:90-100
20 EMPA-REG OUTCOME Trial design Placebo (n=2333) Screening (n=11531) Randomized and treated (n=7020) Empagliflozin 10 mg (n=2345) Study medication was given in addition to standard of care. Primary outcome: 3-point MACE Analysis: Placebo vs. pooled empagliflozin groups Key inclusion criteria: Adults with type 2 diabetes established CVD Empagliflozin 25 mg (n=2342) BMI 45 kg/m 2 ; HbA1c 7 10%; egfr 30 ml/min/1.73m 2 (MDRD) Zinman B et al. N Engl J Med 2015;373:2117
21 EMPA-REG OUTCOME Trial design Placebo (n=2333) Screening (n=11531) Randomized and treated (n=7020) Empagliflozin 10 mg (n=2345) BASELINE FEATURES Age 63 years, BMI 31 kg/m2, 72% male A1c 8.1%, LDL 86 mg/dl, egfr 74 ml/min/1.73m 2 (26% CKD-3) DM meds: 74%, 43% Sulfonylurea, 48% Insulin CVD: 76% CAD, 46% MI, 10% HF, 23% stroke, 21% PAD Empagliflozin 25 mg (n=2342) CV meds: 77% statin, 81% ACEI/ARB, 65% BB, 43% diuretic, 83% ASA Zinman B et al. N Engl J Med 2015;373:2117
22 Primary outcome: 3-point MACE HR 0.86 (95.02% CI 0.74, 0.99) p=0.0382* 14% N=7020 Cumulative incidence function. MACE, Maj Adverse Cardiovascular Event; HR, hazard ratio. * Two-sided tests f superiity were conducted (statistical significance was indicated if p ) Zinman B et al. N Engl J Med 2015;373:2117
23 CV death HR 0.62 (95% CI 0.49, 0.77) p< % N=7020 Cumulative incidence function. HR, hazard ratio Zinman B et al. N Engl J Med 2015;373:2117
24 Categies of CV death Patients with event (%) Empagliflozin Placebo (n=4687) (n=2333) HR (95% CI) CV death* 172 (3.7%) 137 (5.9%) 0.62 (0.49, 0.77) Sudden death 53 (1.1%) 38 (1.6%) 0.69 (0.45, 1.04) Wsening of heart failure 11 (0.2%) 19 (0.8%) 0.29 (0.14, 0.61) Acute MI 15 (0.3%) 11 (0.5%) 0.68 (0.31, 1.48) Stroke 16 (0.3%) 11 (0.5%) 0.72 (0.33, 1.55) Cardiogenic shock 3 (0.1%) 3 (0.1%) Other 74 (1.6%) 55 (2.4%) 0.66 (0.47, 0.94) Not assessable 71 (1.5%) 53 (2.3%) Cox regression analysis. *Based on adjudication. Insufficient data f the adjudication committee to categize cause of death. HR, hazard ratio; CI, confidence interval; CV, cardiovascular; MI, myocardial infarction. Cardiogenic shock: HR and 95% CI not calculated as <14 patients with events. 0,13 0,25 0,50 1,00 2,00 Favs empagliflozin Favs placebo Fitchett D et al. ACC.16, Chicago, IL
25 CV death, MI and stroke Patients with event/analysed Empagliflozin Placebo HR (95% CI) p-value 3-point MACE 490/ / (0.74, 0.99)* CV death 172/ / (0.49, 0.77) < Non-fatal MI 213/ / (0.70, 1.09) Non-fatal stroke 150/ / (0.92, 1.67) Cox regression analysis. MACE, Maj Adverse Cardiovascular Event; HR, hazard ratio; CV, cardiovascular; MI, myocardial infarction *95.02% CI 0,25 0,50 1,00 2,00 Favours empagliflozin Favours placebo Zinman B et al. N Engl J Med 2015;373:2117
26 Ongoing Diabetes CV Outcomes Trials Involving SGLT2 Inhibits CANVAS DECLARE NCT * Study CANVAS 1 Study DECLARE 2 Study NCT SGLT2 inhibit Canagliflozin SGLT2 inhibit Dapagliflozin SGLT2 inhibit Ertugliflozin Comparat Placebo N 4300 Results 2017 Comparat Placebo N 22,200 Results 2019 Comparat Placebo N 3900 Results 2020 CANVAS-R Renal outcomes in T2D patients at high CV risk CREDENCE Renal & CV outcomes in T2D patients with nephropathy (GFR 30-<90 with UACR 300-<5000 mg/g Cr) *Not approved by FDA EMA 1. Neal B, et al. Am Heart J. 2013;166: ; 2. Clinicaltrials.gov. NCT ; 3. Clinicaltrials.gov. NCT
27 Will They Wear Out the Kidney? Small, reversible decreases in GFR. Less effective when kidney function is reduced. (Not indicated when egfr <60 (dapa) <45 (cana, empa) Decreases in albuminuria Loss of glucose reabsption appears to be safe in non-diabetic patients with nmal egfr (i.e., Familial Renal Glucosuria) Unclear what long-term effect of persistent glucosuria will be in people with diabetes
28 Incident wsening nephropathy* 41% *Defined as: Progression to macroalbuminuria (UACR >300), N=7020 doubling of SCr (with egfr 45), dialysis/transplant, renal death Kaplan-Meier estimate. Hazard ratio based on Cox regression analyses. Wanner C, et al. N Engl J Med 2016;DOI: /NEJMoa
29 Incident wsening nephropathy (& components) Empagliflozin Placebo n with event/ N analyzed Hazard ratio (95% CI) p-value Incident wsening nephropathy New onset macroalbuminuria 525/ / (0.53, 0.70) < / / (0.54, 0.72) < Doubling of serumcreatinine * 70/ / (0.39, 0.79) Initiation of renal replacement therapy *Accompanied by egfr (MDRD) 45 ml/min/1.73m 2. Cox regression analyses. 0,13 0,25 0,50 1,00 2,00 13/ / (0.21, 0.97) Favours empagliflozin Favours placebo Wanner C, et al. N Engl J Med 2016;DOI: /NEJMoa
30 ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Sulfonylurea high moderate risk gain hypoglycemia low Thiazolidinedione high low risk gain edema, HF, fxs low DPP-4 inhibit intermediate low risk neutral rare high SGLT2 inhibit intermediate low risk loss GU, dehydration high GLP-1 recept agonist high low risk loss GI high Insulin (basal) highest high risk gain hypoglycemia variable Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Diabetes Care 2015;38:140-9; Diabetologia 2015;58: Triple therapy Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): TZD DPP-4-i Thiazolidinedione SU DPP-4-i DPP-4 Inhibit SU TZD SGLT-2 Inhibit SU TZD GLP-1 recept agonist SU TZD Insulin (basal) TZD DPP-4-i SGLT2-i SGLT2-i SGLT2-i DPP-4-i Insulin SGLT2-i GLP-1-RA GLP-1-RA Insulin Insulin GLP-1-RA Insulin Insulin Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add GLP-1-RA mealtime insulin. In refracty patients consider adding TZD SGL T2-i: Basal Insulin Mealtime Insulin GLP-1-RA 30
31 ADA-EASD Position Statement on the Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Sulfonylurea high moderate risk gain hypoglycemia low Thiazolidinedione high low risk gain edema, HF, fxs low DPP-4 inhibit intermediate low risk neutral rare high SGLT2 inhibit intermediate low risk loss GU, dehydration high GLP-1 recept agonist high low risk loss GI high Insulin (basal) highest high risk gain hypoglycemia variable Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Diabetes Care 2015;38:140-9; Diabetologia 2015;58: Triple therapy Sulfonylurea If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): TZD DPP-4-i Thiazolidinedione SU DPP-4-i DPP-4 Inhibit SU TZD SGLT-2 Inhibit SU TZD GLP-1 recept agonist SU TZD Insulin (basal) TZD DPP-4-i SGLT2-i SGLT2-i SGLT2-i DPP-4-i Insulin SGLT2-i GLP-1-RA GLP-1-RA Insulin Insulin GLP-1-RA Insulin Insulin Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add GLP-1-RA mealtime insulin. In refracty patients consider adding TZD SGL T2-i: Basal Insulin Mealtime Insulin GLP-1-RA 31
32 Side effects stem directly from their mechanism of action increased urination, possible dehydration, and increase in GU infections. DKA is an emerging concern, mainly in T1DM (not indicated) but potentially in (presumably) insulin deficient T2DMs. SGLT2 Inhibition in T2DM : Current Position, Future Promise SUMMARY The SGLT 2-i s are the newest categy of T2DM drugs. They wk by augmenting urinary glucose excretion and are effective at any stage of disease, so long as there is sufficient renal function. They are not associated with hypoglycemia when used as monotherapy other non-hypoglycemic agents. SGLT 2-i s result in modest improvements in some CV risk facts (weight, BP.) The first SGLT2-i CVOT to rept, EMPA-REG OUTCOME, showed a surprising effect of empagliflozin to decrease 3-point MACE, primarily through a 38% relative risk reduction in CV death (ARR = 2.2%).
33 SGLT2 Inhibition, Diabetes and CVD: Where Does This Fit in CV Risk Management? ESC Congress, Rome, Italy 28 August, 2016 SGLT2 Inhibition in T2DM Management: Current Position and Future Promise Silvio E. Inzucchi MD Yale University New Haven, Connecticut, USA
SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationLEADER and EMPA-REG. John Buse, MD, PhD. University of North Carolina School of Medicine Chapel Hill, NC, USA. Duality of Interest Declaration
1 LEADER and EMPA-REG John Buse, MD, PhD University of Nth Carolina School of Medicine Chapel Hill, NC, USA Duality of Interest Declaration I rept the following potential duality/dualities of interest
More informationManagement of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA) and the European Association f the Study of Diabetes
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationSilvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine
Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationTreating Diabetes To Lower Cardiovascular Disease Risk
Treating Diabetes To Lower Cardiovascular Disease Risk Anne Peters, MD Profess, USC Keck School of Medicine Direct, USC Clinical Diabetes Programs Disclosure of Financial Relationships 2015 Consultantship
More informationSince 2009, the medical management of
Article Real-wld experience of SGLT2 inhibits: A useful addition to the arsenal of antidiabetes medication. An Irish perspective Patricia Harkin, Ann Fitzpatrick, Ber Lynch, Siobhan Hatton, Ronan Canavan,
More informationInsulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationSGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS
SGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS Dr. Kirtida Acharya National chair, Diabetes Kenya Consultant Endocrinologist/Diabetologist, MP Shah Hospital KCS Symposium, 30 th June, 2017 Sarova Whitesands,
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDISCLOSURES. Learning objectives NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Investigator Initiated Trial Support:
NAVIGATING THE TREATMENT OF TYPE 2 DIABETES: WHAT S NEW? Jane E-B Reusch MD Professor of Medicine, Biochemistry and Bioengineering Associate Director Center for Women s Health Research University of Colorado
More informationAmbrish Mithal MD, DM
Ambrish Mithal MD, DM Chairman, Division of Endocrinology and Diabetes Medanta The Medicity Padma Bhushan Awardee 2015, Member Governing Council, Indian Council of Medical Research (ICMR) Dr Mithal is
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationNew Approaches for Treating Challenging Patients with Diabetes
New Approaches for Treating Challenging Patients with Diabetes Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationSGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney?
SGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney? Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen The Netherlands Disclosures:
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationDiabetes Mellitus: Overview and Guidelines
Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationA Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Silvio E. Inzucchi, MD A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationAsk the Experts: Practice Pearls for SGLT2 Inhibitors
Ask the Experts: Practice Pearls for SGLT2 Inhibitors Presented as a Live Webinar Thursday, March 12, 2015 12:00 p.m. 1:00 p.m. ET www.ashpadvantage.com/go/sglt2/experts Planned by ASHP Advantage and supported
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationManagement of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS
Management of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationFuture Clinical Impact to SGLT2i in the Treatment of Diabetes
Future Clinical Impact to SGLT2i in the Treatment of Diabetes Imam Subekti Division of Endocrinology and Metabolism, Department of Internal Medicine Ciptomangunkusumo Hospital / Faculty of Medicine, Universitas
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationEffects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis
Elmer ress Original Article J Clin Med Res. 2016;8(3):237-243 Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis Hisayuki
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationIl blocco del cotrasportatore. della terapia antiiperglicemica. Anna Solini
Il blocco del cotrasportatore sodioglucosio come target della terapia antiiperglicemica Anna Solini Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell Area Critica Università di Pisa Grant
More informationDiscussant Primary and Secondary Prevention of CV Events in the CANVAS Program
Discussant Primary and Secondary Prevention of CV Events in the CANVAS Program M. Angelyn Bethel, MD Associate Professor of Diabetes and Endocrinology University of Oxford UK Aims & major findings Aims:
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationClass Update: Sodium glucose Cotransporter 2 (SGLT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSGLT2 Inhibitors From Discovery to Clinical Practice
SGLT2 Inhibitors From Discovery to Clinical Practice Sunder Mudaliar, MD, FRCP (Edin), FACP, FACE Clinical Professor of Medicine University of California, San Diego Staff Physician VA San Diego Healthcare
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More information